Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.44 |
| ▸ | STAT3 | P40763 | 2/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18553862 | 0.90 | PDE4A (0.52) | CYP1A2CYP2C9CYP3A4CYP2C19TSHR | |
| SCHEMBL6464814 | 0.79 | MEN1 (0.53) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL10771572 | 0.78 | MEN1 (0.55) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL498487 | 0.76 | MEN1 (0.54) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL9579837 | 0.74 | HTT (0.54) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL1490943 | 0.72 | MEN1 (0.58) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL7713203 | 0.71 | ALDH1A1 (0.64) | HSD17B2ALOX5NFKB1CYP3A4TSHR | |
| SCHEMBL2524593 | 0.70 | HTT (0.59) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL3691263 | 0.69 | MEN1 (0.48) | MEN1KMT2ASLC22A6SLC22A8RAB9A | |
| SCHEMBL3853620 | 0.68 | MEN1 (0.72) | MEN1KMT2ASLC22A6SLC22A8RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1085860-B1 | FORMULATIONS FOR THE TREATMENT OF GASTRO-OESOPHAGEAL REFLUX | RECKITT BENCKISER HEALTHCARE (GB) | 2002-10-16 | — | — | EP | claimed |
| CN-105358179-A | Design of curcumin-peptide complex having improved solubility and function compared with curcumin and method for preparing curcumin-peptide complex | ANYGEN CO LTD | 2016-02-24 | — | — | CN | disclosed |
| US-8475850-B2 | Methods and compositions for heavy metal detoxification | METAPROTEOMICS, LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8241674-B2 | Methods and compositions for heavy metal detoxification | METAPROTEOMICS, LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120189721-A1 | METHODS AND COMPOSITIONS FOR HEAVY METAL DETOXIFICATION | METAPROTEOMICS, LLC (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2152684-A1 | METHODS AND COMPOSITIONS FOR HEAVY METAL DETOXIFICATION | Metaproteomics, LLC (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090155382-A1 | Methods and Compositions for Heavy Metal Detoxification | METAPROTEOMICS, LLC (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008140842-A1 | METHODS AND COMPOSITIONS FOR HEAVY METAL DETOXIFICATION | METAPROTEOMICS, LLC (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1085860-B1 | FORMULATIONS FOR THE TREATMENT OF GASTRO-OESOPHAGEAL REFLUX | RECKITT BENCKISER HEALTHCARE (GB) | 2002-10-16 | — | — | EP | disclosed |
| EP-1085860-A1 | FORMULATIONS FOR THE TREATMENT OF GASTRO-OESOPHAGEAL REFLUX | RECKITT & COLMAN PRODUCTS LIMITED (GB) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999063986-A1 | FORMULATIONS FOR THE TREATMENT OF GASTRO-OESOPHAGEAL REFLUX | RECKITT & COLMAN PRODUCTS LIMITED (GB) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155382-A1 | Methods and Compositions for Heavy Metal Detoxification | GSTM2, GSTA2, GSTM1 | MEN1 4847/4885KMT2A 2360/4885SLC22A6 764/4885 |
| US-20120189721-A1 | METHODS AND COMPOSITIONS FOR HEAVY METAL DETOXIFICATION | GSTM2, GSTA2, GSTM1 | MEN1 4847/4885KMT2A 2360/4885SLC22A6 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.